Víctor Eduardo Vásquez Ortiz

Mr. Víctor Eduardo Vásquez Ortiz

Jicamarca Radio Observatory

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2009 in Cancer Letters
Verified
Journal Article
Closed access
VOVíctor Eduardo Vásquez Ortiz
Víctor Eduardo Vásquez Ortiz
JFJanusz Franco-Barraza
Janusz Franco-Barraza
ASAna Luisa Esparza Silva
Ana Luisa Esparza Silva
GPGisela Du Pont
Gisela Du Pont
GSGloria Soldevila
Gloria Soldevila
EGEduardo A. García-Zepeda
Eduardo A. García-Zepeda

1 July 2012 in Advances In Space Research
Verified
Journal Article
Closed access
VOVíctor Eduardo Vásquez Ortiz
Víctor Eduardo Vásquez Ortiz
RNRafael Navarro-González
Rafael Navarro-González
LFLauren Fletcher
Lauren Fletcher
SPSaúl Perez-Montaño
Saúl Perez-Montaño
RCReneé Condori-Apaza
Reneé Condori-Apaza
CMChristopher P. Mckay
Christopher P. Mckay

1 April 2010 in Archives of Medical Research
Verified
Journal Article
Closed access
JFJanusz Franco-Barraza
Janusz Franco-Barraza
VOVíctor Eduardo Vásquez Ortiz
Víctor Eduardo Vásquez Ortiz
HZHoracio Zamudio-Meza
Horacio Zamudio-Meza
ACAida Castillo
Aida Castillo
EGEduardo A. García-Zepeda
Eduardo A. García-Zepeda
IMIsaura Meza
Isaura Meza

1 January 2012 in Advances In Space Research
Verified
Journal Article
Closed access
LFLauren E. Fletcher
Lauren E. Fletcher
VOVíctor Eduardo Vásquez Ortiz
Víctor Eduardo Vásquez Ortiz
SPSaul Perez-Montaño
Saul Perez-Montaño
RCRenee M. Condori-Apaza
Renee M. Condori-Apaza
CCCatharine A. Conley
Catharine A. Conley
CMChristopher P. McKay
Christopher P. McKay

16 November 2017 in International Journal of Astrobiology
Verified
Journal Article
Open access
PDF file
David A. RamirezDavid A. Ramirez
David A. Ramirez
JKJan Kreuze
Jan Kreuze
WAWalter Amoros
Walter Amoros
VOVíctor Eduardo Vásquez Ortiz
Víctor Eduardo Vásquez Ortiz
JRJoel Ranck
Joel Ranck
WYWendy Yactayo
Wendy Yactayo
One of the future challenges to produce food in a Mars environment will be the optimization of resources through the potential use of the Martian substratum for growing crops as a part of bioregenerative food systems.In vitroplantlets from 65 potato genotypes were rooted in peat-pellets substratum and transplanted in pots filled with Mars-like soil from La Joya desert in Southern Peru. The Mars-like soil was characterized by extreme salinity (an electric conductivity of 19.3 and 52.6 dS m−1under 1 : 1 and saturation extract of the soil solution, respectively) and plants grown in it were under sub-optimum physiological status indicated by average maximum stomatal conductance <50 mmol H2O m−2s−1even after irrigation. 40% of the genotypes survived and yielded (0.3–5.2 g tuber plant−1) where CIP.397099.4, CIP.396311.1 and CIP.390478.9 were targeted as promising materials with 9.3, 8.9 and 5.8% of fresh tuber yield in relation to the control conditions. A combination of appropriate genotypes and soil management will be crucial to withstand extreme salinity, a problem also important in agriculture on Earth that requires more detailed follow-up studies.

Verified
Journal Article
Open access
PDF file
VOVíctor Eduardo Vásquez Ortiz
Víctor Eduardo Vásquez Ortiz
JMJaciel Medina-Tamayo
Jaciel Medina-Tamayo
EZEduardo Garcia Zepeda
Eduardo Garcia Zepeda
Chemokines are a burgeoning family of chemotactic cytokines displaying a broad array of functions such as regulation of homeostatic leukocyte traffic and development, as well as activating the innate immune system. Their role in controlling early and late inflammatory stages is now well recognized. An improper balance either in chemokine synthesis or chemokine receptor expression contributes to various pathological disorders making chemokines and their receptors a useful therapeutic target. Research in this area is progressing rapidly, and development of novel agents based on chemokine/ chemokine receptors antagonist functions are emerging as attractive alternative drugs. Some of these novel agents include generation of chemokine-derived peptides (CDP) with potential agonist and antagonist effects on inflammation, cancer and against bacterial infections. CDP have been generated mainly from N- and C-terminus chemokine sequences with subsequent modifications such as truncations or elongations. In this review, we present a glimpse of the different pharmacological actions reported for CDP and our current understanding regarding the potential use of CDP alone or as part of the novel therapies proposed in the treatment of microbial infections and cancer.